MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Identifying biomarkers to predict disease progression in early stage Parkinson’s disease patients

    L. Neilson, J. Baird, B. Lobb, H. Vanderjagt, N. Gray, S. O'Connor, J. Quinn (Portland, OR, USA)

    Objective: To evaluate the sensitivity of instrumented measures of motor dysfunction and candidate serological markers of disease to predict disease progression in de novo Parkinson’s…
  • MDS Virtual Congress 2020

    Minor hallucinations in Parkinson’s disease are associated with increased neurofilament plasma levels and reduced white-matter integrity in the inferior longitudinal fasciculus

    H. Bejr-kasem, J. Pagonabarraga, F. Sampedro, S. Martínez-Horta, R. Perez-Gonzalez, J. Marín-Lahoz, A. Horta-Barba, I. Aracil-Bolaños, A. Campolongo, C. Izquierdo, J. Perez-Perez, B. Pascual-Sedano, J. Kulisevsky (Barcelona, Spain)

    Objective: To examine whether patients with Parkinson's disease (PD) and isolated minor hallucinations have increased plasma neurofilament light chain (NfL) levels and/or differences in white…
  • MDS Virtual Congress 2020

    Depression in patients with Parkinson’s disease

    M. Lisak, B. Špiljak (Zagreb, Croatia)

    Objective: The objective of this study was to correlate PD severity with depression. Background: ​​​​Depression is the most common psychiatric disorder in patients with PD. In…
  • MDS Virtual Congress 2020

    Severity of Motor Symptoms in Parkinson’s Disease in Kazakhstan (on the example of the city of Almaty)

    A. Aralbayeva, S. Kamenova, A. Kondybaeva, K. Kuzhibaeva (Almaty, Kazakhstan)

    Objective: Determine the severity of motor symptoms with Parkinson's disease using the MDS-UPDRS scale. Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by…
  • MDS Virtual Congress 2020

    Safety and efficacy of istradefylline, an adenosine A2A receptor antagonist, as a function of baseline dyskinesia (BL-dyskinesia) in Parkinson’s disease (PD): A pooled analysis of 4 studies

    L. Elmer, K. Toyama, J. Parno, D. Braccia, R. Ristuccia, A. Mori (Toledo, OH, USA)

    Objective: To evaluate the effect of BL-dyskinesia on the efficacy and safety of istradefylline in 4 randomized, placebo-controlled, double-blind, phase 2b/3 trials. Background: Istradefylline, a…
  • MDS Virtual Congress 2020

    Impact of safinamide on non-motor and motor experiences of daily living: Primary results from the prospective, observational ProGo study

    S. Isaacson, T. Clinch, E. Farbman, R. Pahwa (Boca Raton, FL, USA)

    Objective: Evaluate the effect of safinamide treatment on non-motor and motor experiences of daily living as assessed using the MDS-UPDRS (Parts I nm-EDLand II m-EDL).…
  • MDS Virtual Congress 2020

    Open data sharing of the Parkinson’s Outcomes Project: A global, longitudinal clinical study of over 13,000 people with Parkinson’s disease

    C. Marras, A. Naito, N. Dahodwala, A. Ramirez-Zamora, M. Rafferty, M. Neault, S. Wu, J. Beck, R. DeLeon, T. Davis (Miami, FL, USA)

    Objective: To describe the newly developed Parkinson’s Outcomes Project data sharing policy to the entire research community with a long-term goal of accelerating novel hypothesis…
  • MDS Virtual Congress 2020

    Effects of Nabilone on non-motor symptoms of Parkinson´s Disease: A randomised placebo-controlled study (The NMS-Nab Study)

    M. Peball, F. Krismer, H.G Knaus, A. Djamshidian, M. Werkmann, F. Carbone, P. Ellmerer, B. Heim, K. Marini, D. Valent, G. Goebel, H. Ulmer, H. Stockner, G.K Wenning, R. Stolz, K. Krejcy, W. Poewe, K. Seppi (Innsbruck, Austria)

    Objective: To investigate the effects of the synthetic cannabinoid nabilone for the treatment of non-motor symptoms in Parkinson´s disease (PD) in a controlled fashion. Background:…
  • MDS Virtual Congress 2020

    Resistance Training on Postural Control in Parkinson’s Disease: a Randomized Controlled Trial

    C. Souza, J. Chen, D. Francato, A. Barbosa, M. Voos, E. Barbosa, H. Chien (Sao Paulo, Brazil)

    Objective: To evaluate changes in postural control following RT using static posturography and clinical functional balance tests in Parkinson’s Disease patients Background: Muscle weakness affects…
  • MDS Virtual Congress 2020

    Clinical research of serum uric acid levels in Parkinson’s disease

    J.W Wu, T. Wang (Wuhan, China)

    Objective: To analyzed the variation of uric acid (UA) traits in different Hoehn-Yahr staging in Parkinson's disease (PD). Background: PD is a common neurodegenerative disease.…
  • « Previous Page
  • 1
  • …
  • 125
  • 126
  • 127
  • 128
  • 129
  • …
  • 149
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley